Cortisol, a hormone produced by the adrenal glands, is essential for regulating metabolism and stress responses. However, chronically elevated cortisol levels may contribute to metabolic dysfunction, including non-alcoholic fatty liver disease (NAFLD), now termed metabolic dysfunction-associated steatotic liver disease (MASLD). This condition involves excessive fat accumulation in the liver and affects a growing number of people in the UK. Whilst high cortisol can influence liver fat through effects on insulin resistance and lipid metabolism, fatty liver typically develops through multiple interconnected factors including obesity, diet, and genetic predisposition. Understanding the link between cortisol and liver health is important for prevention and management.

Understanding the Link Between High Cortisol and Fatty Liver

Cortisol is a steroid hormone produced by the adrenal glands that plays a vital role in regulating metabolism, immune function, and the body's stress response. Whilst cortisol is essential for normal physiological function, chronically elevated levels can have significant metabolic consequences, including effects on liver health. Non-alcoholic fatty liver disease (NAFLD)—increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD)—is characterised by excessive fat accumulation in the liver in people who consume little or no alcohol. Emerging evidence suggests an association between elevated cortisol and this increasingly common condition.

The connection between high cortisol and fatty liver is primarily mediated through cortisol's effects on glucose and lipid metabolism. Elevated cortisol promotes insulin resistance, increases hepatic glucose production, and enhances lipolysis (the breakdown of fat stores), which collectively contribute to increased delivery of fatty acids to the liver. These metabolic changes create an environment conducive to hepatic steatosis (fatty liver). However, it is important to note that whilst there is biological plausibility and observational evidence linking high cortisol to fatty liver, the relationship is complex and influenced by multiple factors including diet, physical activity, genetic predisposition, and other metabolic conditions. Most cases of fatty liver are driven primarily by obesity and insulin resistance rather than cortisol excess alone.

Key points to understand:

• Cortisol influences how the body processes fats and sugars

• Chronic elevation may contribute to metabolic dysfunction, but is rarely the sole cause of fatty liver

• Fatty liver develops through multiple interconnected pathways

• The relationship is part of a broader metabolic syndrome picture

Understanding this association is important for both prevention and management of liver health, particularly in individuals with conditions associated with elevated cortisol levels.

How Elevated Cortisol Levels Affect Liver Fat Accumulation

The mechanisms by which elevated cortisol may contribute to hepatic fat accumulation are multifaceted and involve several interconnected metabolic pathways. Cortisol exerts its effects primarily through binding to glucocorticoid receptors, which are abundant in liver tissue. Once activated, these receptors influence the expression of numerous genes involved in glucose and lipid metabolism. Much of the mechanistic understanding derives from observational studies in humans and preclinical research.

Insulin resistance and glucose metabolism: Cortisol promotes insulin resistance in peripheral tissues, meaning cells become less responsive to insulin's signals. This leads to compensatory hyperinsulinaemia (elevated insulin levels) and increased hepatic glucose production through gluconeogenesis. The combination of insulin resistance and hyperinsulinaemia creates a metabolic environment that favours fat synthesis in the liver through a process called de novo lipogenesis, where excess glucose is converted into fatty acids.

Lipid metabolism alterations: Elevated cortisol stimulates lipolysis in adipose tissue, releasing free fatty acids into the bloodstream. These fatty acids are then taken up by the liver, where they can be oxidised for energy, re-esterified into triglycerides, or packaged into very-low-density lipoproteins (VLDL) for export. When the influx of fatty acids exceeds the liver's capacity for oxidation and export, triglycerides accumulate within hepatocytes, resulting in steatosis. Additionally, the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) regenerates active cortisol from inactive cortisone in liver and adipose tissue, potentially amplifying local cortisol effects even when circulating levels appear normal.

Inflammatory pathways: Chronic cortisol elevation—particularly in the context of chronic stress or glucocorticoid receptor resistance—may contribute to low-grade inflammation despite cortisol's anti-inflammatory properties at physiological levels. This inflammatory state may impair the liver's ability to process fats efficiently and contribute to progression from simple steatosis to non-alcoholic steatohepatitis (NASH), now termed metabolic dysfunction-associated steatohepatitis (MASH), a more severe form of fatty liver disease characterised by inflammation and potential fibrosis.

These mechanisms demonstrate that cortisol's influence on fatty liver is not through a single pathway but rather through orchestrated metabolic dysregulation affecting multiple organ systems.

Conditions That Raise Cortisol and Increase Fatty Liver Risk

Several medical conditions and circumstances can lead to elevated cortisol levels, potentially increasing the risk of developing fatty liver disease. Understanding these conditions is important for identifying at-risk individuals and implementing appropriate monitoring and management strategies.

Cushing's syndrome represents the most dramatic example of pathological cortisol excess. This rare condition results from prolonged exposure to high cortisol levels, either from endogenous overproduction (pituitary adenomas, adrenal tumours, or ectopic ACTH production) or exogenous glucocorticoid administration. Studies have demonstrated that fatty liver is highly prevalent in Cushing's syndrome, with research suggesting substantial rates in affected individuals. The metabolic complications of this condition extend beyond liver health to include diabetes, hypertension, and cardiovascular disease.

Chronic stress and psychological conditions: Whilst the cortisol elevations associated with chronic psychological stress are generally more modest than those seen in Cushing's syndrome, prolonged activation of the hypothalamic-pituitary-adrenal (HPA) axis may contribute to metabolic dysfunction. Depression, anxiety disorders, and chronic stress have been associated with dysregulated cortisol patterns, though cortisol responses vary considerably between individuals and the direct causal link to fatty liver remains an area of ongoing research.

Metabolic syndrome and obesity: These conditions are associated with altered cortisol metabolism, including increased local cortisol production in adipose tissue through the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). This creates a state of tissue-specific cortisol excess even when circulating levels appear normal.

Exogenous glucocorticoid therapy: Long-term treatment with corticosteroids (such as prednisolone, dexamethasone, or hydrocortisone) for conditions like asthma, rheumatoid arthritis, or inflammatory bowel disease can produce effects similar to endogenous cortisol excess. Patients on long-term glucocorticoid therapy require careful monitoring for metabolic complications, including glucose control, blood pressure, weight, bone health, and—when clinically indicated—liver function. It is essential not to stop long-term corticosteroid treatment abruptly; any dose reduction should be agreed with your clinician to avoid adrenal insufficiency.

Recognising Symptoms of High Cortisol and Liver Problems

Identifying elevated cortisol and fatty liver disease can be challenging because both conditions often develop gradually and may remain asymptomatic in their early stages. However, recognising the clinical features of these conditions is essential for timely diagnosis and intervention.

Signs of elevated cortisol (hypercortisolism):

• Physical changes: Central weight gain with fat accumulation around the abdomen and face (moon face), whilst limbs may appear thin; purple striae (stretch marks) on the abdomen, thighs, or arms; easy bruising and thin skin

• Metabolic disturbances: New-onset or worsening diabetes, hypertension, and elevated cholesterol

• Musculoskeletal effects: Muscle weakness, particularly in the proximal muscles (hips and shoulders); reduced bone density leading to osteoporosis

• Psychological symptoms: Mood changes, depression, anxiety, irritability, or cognitive difficulties

• Other features: Irregular menstrual periods in women, reduced libido, increased susceptibility to infections

Symptoms of fatty liver disease:

Most individuals with simple hepatic steatosis experience no symptoms. When present, symptoms are typically non-specific and may include:

• Persistent fatigue and general malaise

• Discomfort or dull ache in the right upper abdomen

• Unexplained weight loss (in advanced disease)

• In more advanced stages (cirrhosis): jaundice, ascites (fluid accumulation in the abdomen), confusion, or bleeding tendencies

Initial tests for suspected Cushing's syndrome:

If Cushing's syndrome is suspected, your GP may arrange initial screening tests, which typically include:

• 1 mg overnight dexamethasone suppression test

• Late-night salivary cortisol measurement

• 24-hour urinary free cortisol collection

Tests are usually repeated to confirm abnormal results, and referral to an endocrinologist is arranged if results are abnormal or clinical suspicion remains high.

Assessing fatty liver and fibrosis risk:

NICE guidance (NG49) recommends risk stratification for people with suspected NAFLD using the FIB-4 score, which estimates fibrosis risk based on age, liver enzymes, and platelet count:

• Age under 65: FIB-4 <1.3 indicates low risk; >3.25 indicates high risk

• Age 65 and over: FIB-4 <2.0 indicates low risk; >2.67 indicates high risk

For indeterminate results, the Enhanced Liver Fibrosis (ELF) blood test may be used as a second-line assessment (NICE DG34). Referral to hepatology is recommended if high risk or advanced fibrosis is suspected, or if liver function tests remain persistently abnormal.

Urgent red flags—seek immediate medical attention (999 or A&E) if you experience:

• Jaundice (yellowing of skin or eyes) with fever

• Vomiting blood or passing black, tarry stools

• Marked confusion or drowsiness

• Severe or rapidly increasing abdominal swelling

• Rapidly progressive Cushingoid features with profound muscle weakness or very low potassium

When to contact your GP:

You should arrange an appointment with your GP if you experience:

• Unexplained weight gain, particularly around the abdomen and face

• Persistent fatigue alongside other symptoms mentioned above

• New or worsening diabetes or hypertension

• Abnormal liver function tests detected during routine blood work

• Any symptoms suggesting liver disease

Early detection through clinical assessment and appropriate investigations allows for timely intervention and may prevent progression to more serious liver disease.

Managing Cortisol Levels to Support Liver Health

Effective management of elevated cortisol and protection of liver health requires a comprehensive approach tailored to the underlying cause and individual circumstances. The strategy differs depending on whether cortisol elevation is pathological (as in Cushing's syndrome) or related to lifestyle and metabolic factors.

Medical management of pathological hypercortisolism:

For individuals with Cushing's syndrome, treatment focuses on addressing the underlying cause. This may involve:

• Surgical intervention: Transsphenoidal surgery for pituitary adenomas or adrenalectomy for adrenal tumours

• Medical therapy: Medications to reduce cortisol production when surgery is not feasible or as bridging therapy. UK-licensed options include: – Osilodrostat (Isturisa): Licensed for Cushing's disease; requires monitoring for adrenal insufficiency and QT interval prolongation – Pasireotide (Signifor): Licensed for Cushing's disease; requires close glucose monitoring due to risk of hyperglycaemia – Ketoconazole (Ketoconazole HRA): Used under specialist supervision; requires regular liver function tests due to hepatotoxicity risk – Metyrapone (Metopirone): May be used off-label for treatment under specialist care; monitor blood pressure and potassium

• Glucocorticoid dose optimisation: For those on long-term corticosteroid therapy, working with specialists to use the lowest effective dose and considering steroid-sparing agents

These medicines have important safety considerations. Your specialist will arrange appropriate monitoring, and you should report any suspected side effects via the MHRA Yellow Card scheme at https://yellowcard.mhra.gov.uk or search for 'Yellow Card' in the Google Play or Apple App Store.

Lifestyle interventions for cortisol regulation and liver health:

For individuals with stress-related cortisol dysregulation or metabolic syndrome, lifestyle modifications form the cornerstone of management:

• Dietary modifications: Adopting a balanced diet rich in vegetables, fruits, whole grains, and lean proteins whilst limiting refined carbohydrates, saturated fats, and processed foods. The Mediterranean diet pattern has evidence supporting both metabolic health and liver fat reduction.

• Regular physical activity: UK Chief Medical Officers recommend at least 150 minutes of moderate-intensity aerobic activity weekly, plus muscle-strengthening activities on at least 2 days per week. Exercise improves insulin sensitivity, aids weight management, and may help regulate cortisol patterns.

• Weight management: Weight loss of 7–10% or more of body weight can lead to histological improvement in NASH/MASH, whilst loss of 5% or more reduces steatosis. Even modest weight loss improves metabolic parameters.

• Stress management techniques: Cognitive behavioural therapy, mindfulness meditation, adequate sleep (7–9 hours nightly), and relaxation techniques may help regulate HPA axis function.

• Alcohol limitation: Following UK Chief Medical Officers' guidance of no more than 14 units weekly, spread over at least 3 days, with several alcohol-free days each week.

Monitoring and follow-up:

Regular monitoring is essential and typically includes:

• Liver fibrosis risk stratification: Calculate FIB-4 score (age <65: <1.3 low risk, >3.25 high risk; age ≥65: <2.0 low risk, >2.67 high risk). For indeterminate results, the Enhanced Liver Fibrosis (ELF) test may be used as a second-line assessment.

• Referral criteria: Refer to hepatology if high risk or advanced fibrosis is suspected, or if liver function tests remain persistently abnormal.

• Assessment of metabolic parameters: Glucose, lipids, blood pressure.

• Evaluation of cortisol status: Through appropriate biochemical testing when indicated.

If you have concerns about cortisol levels or liver health, discuss them with your GP, who can arrange appropriate investigations and refer to specialist services when necessary. Early intervention offers the best opportunity to prevent progression of liver disease and address the metabolic consequences of cortisol excess.

Frequently Asked Questions